# Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer

> **NCT06377722** · PHASE2 · TERMINATED · sponsor: **Fundacion Oncosur** · enrollment: 18 (actual)

## Conditions studied

- Renal Cell Carcinoma Metastatic
- Renal Cell Carcinoma Stage IV
- Renal Cell Carcinoma Stage III

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT06377722
- **Lead sponsor:** Fundacion Oncosur
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-01
- **Primary completion:** 2022-08-09
- **Final completion:** 2022-08-09
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** The achieved number of samples has been smaller than the planned 50 thus, a mainly descriptive final result analysis was conducted, as presented herein.
- **Last updated:** 2024-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06377722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06377722, "Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06377722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*